New pre-charged Ni Sepharose High Performance medium offers highest binding capacity on the market today
Piscataway, NJ – A new affinity chromatography medium announced today by Amersham Biosciences, the life sciences business of Amersham (LSE:, NYSE:, OSE: AHM), offers optimized purification of His-tagged proteins. Ni Sepharose(tm) High Performance provides better protein binding capacity, negligible Ni leakage and compatibility with a wide range of reducing agents, detergents, denaturants and other additives.
The 34 µm bead matrix offers the highest binding capacity available on the market today to provide more concentrated samples, higher efficiency, time savings and increased yield. With negligible Ni leakage, the medium minimizes protein precipitation, and increases purity as well as yield.
Allan Simpson, Vice President Laboratory Separations at Amersham Biosciences comments, “Ni Sepharose High Performance is optimized for the purification of His-tagged proteins. Scientists in industrial and academic labs utilizing this new medium from Amersham Biosciences will have no difficulty translating its advantages into greater purity, higher yields and increased activity, as well as greater operational flexibility.”
In addition to lab packs, Ni Sepharose High Performance is available as pre-packed HisTrap(tm) HP columns and HisTrap HP Kit for convenience and time-saving advantages. These HisTrap HP columns can be used with a syringe, a laboratory pump or chromatography systems such as ÄKTA(tm)design from Amersham Biosciences.
Amersham Biosciences, the life sciences business of Amersham (LSE: NYSE: OSE: AHM), is a world leader in developing and providing integrated systems and solutions for disease research, drug development and manufacture. Our systems are used to uncover the function of genes and proteins, for the discovery and development of drugs and for the manufacture of biopharmaceuticals. The customers for Amersham Biosciences’ products and technology are pharmaceutical and biotechnology companies and research and academic institutions, principally in North America, Europe, Latin America and Asia. More information about Amersham Biosciences is available at www.amershambiosciences.com